Antiinflammatory effects of soluble complement receptor type 1 promote rapid recovery of ischemia/reperfusion injury in rat small intestine

Clin Immunol. 1999 Feb;90(2):266-75. doi: 10.1006/clim.1998.4635.

Abstract

We examined the effect of soluble complement receptor type 1 (sCR1) on mucosal injury and inflammation in a rat model of ischemia/reperfusion. Groups of vehicle- and sCR1-treated rats underwent 30 min of mesenteric ischemia followed by 60 or 120 min of reperfusion. When compared to vehicle-treated rats, treatment with sCR1 (12 mg/kg) prior to 120 min of reperfusion significantly reduced mucosal injury, neutrophil infiltration, leukotriene B4 production, and restored villus height to control levels. The protective effect of sCR1 evident at 120 min of reperfusion was not observed at 60 min of reperfusion despite rapid inactivation of complement. These data suggest that complement inhibition minimized mucosal disruption by facilitating mucosal restitution or interrupting the inflammatory process. Delayed administration of sCR1 for 30 or 60 min into the reperfusion period progressively reduced the protection. sCR1-mediated rapid recovery of rat intestine after ischemia/reperfusion underscores the fundamental role of complement activation in neutrophil-mediated tissue injury.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / isolation & purification
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Complement Activation
  • Disease Models, Animal
  • Hemodynamics
  • Intestinal Mucosa / blood supply
  • Intestinal Mucosa / injuries
  • Intestinal Mucosa / pathology
  • Intestine, Small / blood supply*
  • Intestine, Small / injuries*
  • Intestine, Small / pathology
  • Leukotriene B4 / biosynthesis
  • Male
  • Neutrophils / pathology
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Complement 3b / isolation & purification
  • Receptors, Complement 3b / therapeutic use*
  • Reperfusion Injury / immunology
  • Reperfusion Injury / pathology
  • Reperfusion Injury / therapy*
  • Solubility

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Receptors, Complement 3b
  • Leukotriene B4